Skip header and navigation

4 records – page 1 of 1.

Ulcerative proctitis

https://libcat.nshealth.ca/en/permalink/chpams35311
Nova Scotia Health Authority. GI Clinic. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1422
Available Online
View Pamphlet
Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. GI Clinic
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (4 p.) : digital, PDF file
Subjects (MeSH)
Colitis, Ulcerative
Inflammatory Bowel Diseases
Subjects (LCSH)
Ulcerative colitis
Inflammatory bowel diseases
Abstract
Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
Responsibility
Prepared by: GI Clinic
Pamphlet Number
1422
Less detail

5-Aminosalicylate (5-ASA) for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1483
Available Online
View Pamphlet
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Alternate Title
5-Aminosalicylate (5-ASA) for IBD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Crohn Disease - drug therapy
Colitis - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Colitis
Abstract
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
Notes
Previous title: 5-Aminosalicylate (5-ASA)
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1483
Less detail

Vedolizumab (Entyvio) therapy

https://libcat.nshealth.ca/en/permalink/chpams35620
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1623
Available Online
View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when und…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (11 p.) : digital, PDF file
Subjects (MeSH)
Gastrointestinal Agents
Colitis, Ulcerative - drug therapy
Crohn Disease - drug therapy
Subjects (LCSH)
Gastrointestinal agents
Ulcerative colitis
Crohn's disease
Specialty
Medications
Abstract
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when undergoing this treatment are provided.
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1623
Less detail

Ustekinumab (Stelara) therapy

https://libcat.nshealth.ca/en/permalink/chpams35722
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1695
Available Online
View Pamphlet
Your IBD health care provider believes treatment with a medication called ustekinumab may help to manage your inflammatory bowel disease (IBD). The brand name for ustekinumab is Stelara®. This pamphlet will give you basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include what ustekinumab is, how it works, how it is given, how long you will need to take it, and how much it will cost. Considerations before you start taki…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (10 p.) : digital, PDF file
Subjects (MeSH)
Ustekinumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Ulcerative colitis
Specialty
Medications
Abstract
Your IBD health care provider believes treatment with a medication called ustekinumab may help to manage your inflammatory bowel disease (IBD). The brand name for ustekinumab is Stelara®. This pamphlet will give you basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include what ustekinumab is, how it works, how it is given, how long you will need to take it, and how much it will cost. Considerations before you start taking ustekinumab and while you are taking it are listed. Possible side effects, information about pregnancy and breast/chest feeding, and other important things to know are included.
Notes
Previous title: Ustekinumab (Stelara) therapy for Crohn's disease
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1695
Less detail